[go: up one dir, main page]

TNSN98104A1 - Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents

Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.

Info

Publication number
TNSN98104A1
TNSN98104A1 TNTNSN98104A TNSN98104A TNSN98104A1 TN SN98104 A1 TNSN98104 A1 TN SN98104A1 TN TNSN98104 A TNTNSN98104 A TN TNSN98104A TN SN98104 A TNSN98104 A TN SN98104A TN SN98104 A1 TNSN98104 A1 TN SN98104A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
prostaglandin agonists
prostaglandin
Prior art date
Application number
TNTNSN98104A
Other languages
English (en)
Inventor
O'keefe Cameron Kimberly
Andrew Dasilva Jardine Paul
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN98104A1 publication Critical patent/TNSN98104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UN COMPOSE DE FORMULE I DANS LAQUELLE A REPRESENTE L'HYDROGENE OU UN GROUPE HYDROXY, B, Q, Z, K ET M REPRESENTENT DIVERS RADICAUX, L REPRESENTE UNE LIAISON OU UN GROUPE -CO-. ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LE CONTENANT. APPLICATION : UTILISATION DES COMPOSES ET COMPOSITIONS, COMME AGONISTES DE PROSTAGLANDINES, POUR LE TRAITEMENT DE TROUBLES OSSEUX COMPRENANT L'OSTEOPOROSE.
TNTNSN98104A 1997-06-23 1998-06-22 Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. TNSN98104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5057597P 1997-06-23 1997-06-23

Publications (1)

Publication Number Publication Date
TNSN98104A1 true TNSN98104A1 (fr) 2005-03-15

Family

ID=21966050

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98104A TNSN98104A1 (fr) 1997-06-23 1998-06-22 Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.

Country Status (11)

Country Link
US (1) US6531485B2 (fr)
AP (1) AP9801269A0 (fr)
AR (1) AR013118A1 (fr)
AU (1) AU7349298A (fr)
CO (1) CO5080735A1 (fr)
GT (1) GT199800083A (fr)
HR (1) HRP980356A2 (fr)
MA (1) MA26514A1 (fr)
PA (1) PA8452701A1 (fr)
TN (1) TNSN98104A1 (fr)
WO (1) WO1998058911A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60015508T2 (de) 1999-03-05 2005-04-21 Univ Durham C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
EP1507858B1 (fr) * 2002-05-29 2008-09-17 DSM IP Assets B.V. Procede de purification d'une protease aspartique de rhizomucor
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
EP1563846B1 (fr) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Promoteurs de production de facteurs de reparation endogenes
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
NZ555945A (en) 2005-01-14 2011-01-28 Allergan Inc Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
EP2494990A1 (fr) 2005-06-03 2012-09-05 Ono Pharmaceutical Co., Ltd. Agent pour la régénération et/ou la protection des nerfs
GB0518494D0 (en) * 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
US7323591B2 (en) 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
EP2046714B1 (fr) * 2006-06-20 2015-12-09 Allergan, Inc. Dérivés de cyclopentane comme agents antiglaucomes
AU2007272683B2 (en) * 2006-07-10 2012-08-23 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
BRPI0714885B8 (pt) * 2006-07-11 2021-05-25 Allergan Inc compostos terapêuticos e seu uso
JP5453254B2 (ja) * 2007-07-03 2014-03-26 アラーガン インコーポレイテッド 眼圧降下用の治療用置換シクロペンタン類
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
US8592413B2 (en) 2008-05-15 2013-11-26 Allergan, Inc. Therapeutic substituted cyclopentanes
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
CN115298287B (zh) * 2020-04-21 2024-05-14 组合化学工业株式会社 甲烷生成抑制剂组合物及抑制甲烷生成的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888905A (en) 1969-02-17 1975-06-10 Searle & Co Prostaglandin intermediates and optically active isomers thereof
US3980700A (en) * 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
DE2434133C2 (de) * 1974-07-12 1987-03-19 Schering AG, 1000 Berlin und 4709 Bergkamen 15,15-Äthylendioxy-Prostansäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB1521688A (en) 1974-11-01 1978-08-16 May & Baker Ltd Cyclopentane derivatives
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US4197407A (en) 1977-03-30 1980-04-08 American Cyanamid Company Prostenoic acids and esters
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
GT199800083A (es) 1999-12-10
US6531485B2 (en) 2003-03-11
US20030008895A1 (en) 2003-01-09
AR013118A1 (es) 2000-12-13
MA26514A1 (fr) 2004-12-20
WO1998058911A3 (fr) 1999-03-18
WO1998058911A2 (fr) 1998-12-30
AU7349298A (en) 1999-01-04
PA8452701A1 (es) 2000-05-24
HRP980356A2 (en) 1999-02-28
CO5080735A1 (es) 2001-09-25
AP9801269A0 (en) 1999-12-18

Similar Documents

Publication Publication Date Title
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97208A1 (fr) Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99147A1 (fr) Procede d'emulsification
BG104727A (en) Pharmaceutical composition of topiramate
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97161A1 (fr) Aralkyl-et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN97056A1 (fr) Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant